+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study



Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study



Plos One 13(1): E0191129



To evaluate the effects of metformin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients with diabetes using the Taiwanese National Health Insurance Research Database. In total, 7,620 patients were eligible in this study, among them, 3,578 patients were metformin users and 4,042 were non-users. Propensity score matching was used to reduce possible confounding factors. In total, 4,182 patients (2,091 matched pairs) were included in the matched cohort. Cox proportional hazard model with time-dependent covariate were also applied to evaluate the association between metformin use and overall survival (OS). A total of 3,578 patients were metformin users at the time of diagnosis of NSCLC. Cox proportional hazard model with time-dependent covariate revealed that metformin use was associated with a significantly longer OS (HR: 0.85, 95.0% CI: 0.80-0.90). The survival benefit of metformin use was maintained after propensity score matching at a ratio of 1:1 (HR: 0.90, 95.0% CI: 0.84-0.97). Metformin use is associated with longer OS in inoperable NSCLC patients with diabetes, suggesting a potential anti-tumorigenic effect for metformin. Further research is needed to investigate the actual role of metformin in the treatment of NSCLC patients with diabetes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065549863

Download citation: RISBibTeXText

PMID: 29329345

DOI: 10.1371/journal.pone.0191129


Related references

EGFR mutation status confers survival benefit in non-small cell lung cancer patients undergoing surgical resection of brain metastases: a retrospective cohort study. World Neurosurgery 2019, 2019

Anxiety After Diagnosis Predicts Lung Cancer-Specific and Overall Survival in Patients With Stage III Non-Small Cell Lung Cancer: A Population-Based Cohort Study. Journal of Pain and Symptom Management 53(6): 1057-1065, 2017

Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. Lung Cancer 99: 194-199, 2017

Long-term results of CT-guided percutaneous radiofrequency ablation of inoperable patients with stage Ia non-small cell lung cancer: A retrospective cohort study. International Journal of Surgery 53: 143-150, 2018

Metformin use and survival from lung cancer: A population-based cohort study. Lung Cancer 94: 35-39, 2016

Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. Plos One 12(8): E0181564, 2017

Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. Bmj Open 5(12): E009419, 2016

A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. British Journal of Cancer 92(10): 1834-1836, 2005

Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis. Future Oncology 14(23): 2371-2381, 2018

Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system. International Journal of Cancer 141(2): 254-263, 2017

Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. Journal of Thoracic Oncology 6(5): 934-941, 2011

Biopsy testing in an inoperable, non-small cell lung cancer population-a retrospective, real-life study in Sweden. Journal of Thoracic Disease 7(12): 2226-2233, 2016

Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. Journal of Thoracic Disease 7(3): 346-355, 2015

Metformin therapy associated with survival benefit in lung cancer patients with diabetes. Oncotarget 7(23): 35437-35445, 2018

Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 46(2): 247-254, 2004